Match!
Eugene R Ahn
Cancer Treatment Centers of America
CancerPathologyOncologyPalbociclibMedicine
11Publications
2H-index
23Citations
What is this?
Publications 12
Newest
#1Eugene R AhnH-Index: 2
#2Ricardo H. AlvarezH-Index: 22
Last. Maurie MarkmanH-Index: 66
view all 6 authors...
Background. Current standard of care for HR+HER2+ breast cancer >1cm per NCCN guidelines is chemotherapy with either trastuzumab(T) or trastuzumab and pertuzumab(TP) with anti-HER2 therapy continued for 1 year and anti-hormonal therapy for 5-10 years. Patients with HR+HER2+ breast cancer benefit less from chemotherapy than those with HR-HER2+ breast cancer. Recent studies show that pCR rates with aromatase inhibitor and dual-HER2 blockade for 3-6 months duration range between 21%- 33% with the h...
Source
#1Damien Hansra (Cancer Treatment Centers of America)H-Index: 1
#2Eugene R Ahn (Cancer Treatment Centers of America)H-Index: 2
Last. Ricardo H. Alvarez (Cancer Treatment Centers of America)H-Index: 6
view all 6 authors...
301Background: Obesity is a risk factor for many breast cancer (BC) subtypes & is associated w/ inferior BC outcomes. Here, we investigate the effect of a NCCN based intervention on weight loss (WL...
Source
#1Tareq Al BaghdadiH-Index: 2
#2Susan Halabi (Duke University)H-Index: 60
Last. Richard L. Schilsky (American Society of Clinical Oncology)H-Index: 66
view all 14 authors...
PURPOSEThe Targeted Agent and Profiling Utilization Registry (TAPUR) Study identifies signals of antitumor activity of commercially available targeted agents in patients with advanced cancers that ...
Source
#1Ricardo H. AlvarezH-Index: 6
Last. Richard L. SchilskyH-Index: 66
view all 12 authors...
Source
#1Eugene R AhnH-Index: 2
#2Pam K. MangatH-Index: 2
Last. Richard L. SchilskyH-Index: 66
view all 20 authors...
9041Background: TAPUR is a phase II basket study evaluating anti-tumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations. Results in a cohort ...
#1Ajjai Alva (UM: University of Michigan)H-Index: 19
#2Pam K. Mangat (American Society of Clinical Oncology)H-Index: 2
Last. Richard L. Schilsky (American Society of Clinical Oncology)H-Index: 66
view all 20 authors...
1014Background: TAPUR is a phase II basket study evaluating the anti-tumor activity of commercially available targeted agents in pts with advanced cancers with specific genomic alterations. P is an...
Source
#1Ricardo H. Alvarez (Cancer Treatment Centers of America)H-Index: 6
#2Rebecca Rollins (Cancer Treatment Centers of America)H-Index: 1
Last. At Johnson (Cancer Treatment Centers of America)H-Index: 1
view all 15 authors...
e13112Background: Disparities in breast cancer (BC) care still clearly exist among Whites (W) and African-Americans (AA) racial groups. These disparities resulting in higher mortality among AA comp...
Source
#2Eugene R Ahn (Cancer Treatment Centers of America)H-Index: 2
Last. Ricardo H. Alvarez (Cancer Treatment Centers of America)H-Index: 6
view all 13 authors...
1098Background: MBC is a rare entity comprising less than 1% of breast cancers [Siegel RL 2017]. Due to the low incidence of MBC, information about the genomic landscape of MBC is lacking. Here we ...
Source
#1Eleanor Meisner (UIUC: University of Illinois at Urbana–Champaign)H-Index: 1
#2Rebecca Rollins (Cancer Treatment Centers of America)H-Index: 1
Last. Ricardo H. Alvarez (Cancer Treatment Centers of America)H-Index: 6
view all 16 authors...
1074Background: A recent Phase III study in MBC with gBRCAm, olaparib monotherapy provided a statistical significant and clinically meaningful PFS benefit compared to standard physician of choice treatment. (Robson M, NEJM 2017) Recently, olaparib was FDA approved for MBC with gBRCAm. Methods: IRB-approved analysis of pts underwent to genomic or genetic analysis. Retrospective review charts for pts with MBC who had received ≥2 chemotherapy lines for MBC were tested with genomic or genetic studie...
2 CitationsSource
#1Tareq Al BaghdadiH-Index: 2
#2Susan Halabi (Duke University)H-Index: 60
Last. Richard L. Schilsky (American Society of Clinical Oncology)H-Index: 66
view all 15 authors...
2532Background: The TAPUR Study is a phase II multi‐basket study that evaluates the anti‐tumor activity of commercially available targeted agents in pts with advanced cancers with genomic alteratio...
21 CitationsSource
12